Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,326

Document Document Title
WO/2018/129497A1
The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer ...  
WO/2018/103626A1
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...  
WO/2018/086241A1
The present invention relates to a pH-sensitive ketal-linked cholesterol-zinc phthalocyanine coordination complex and a preparation method therefor and application thereof in medicine. In particular, the present invention relates to the ...  
WO/2018/071544A1
This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)- 2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]ph enanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also...  
WO/2018/068021A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2018/054300A1
Provided is a crystalline form cholic acid derivative free alkali, a preparation method therefor and an application. The chemical name of the cholic acid derivative free alkali is (5R)-5-((2R)-2-((3R,5S,6R,7R,10S,13R)-6-ethyl-3,7-dihydro...  
WO/2018/050099A1
Provided is a panaxdiol-type ginsenoside derivative having a structure as shown in formula I or formula II. Also provided is the use thereof in the preparation of a drug for preventing and treating atherosclerosis. The panaxdiol-type gin...  
WO/2018/029223A1
A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).  
WO/2018/013615A1
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...  
WO/2018/013613A1
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...  
WO/2017/205964A1
Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display c...  
WO/2017/208132A1
A process for the synthesis of 3β-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (I) given below.  
WO/2017/202003A1
Disclosed is a compound of formula (I) as a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt or ester thereof, wherein formula (I) is as defined in the description. The effect of the compound on inhibiting glycogeno...  
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/170564A1
[Problem] To provide a novel DDS having SN-38 as the medicinal component. [Solution] An excellent SN-38 ester derivative with cancer cell proliferation inhibitory activity is provided which is effective in nanodrug production.  
WO/2017/149091A1
The invention relates to a process for the preparation of 11 -methylene steroids through selective olefination of the ketone at position 11. The resulting products are useful intermediates in the preparation of several pharmaceutically a...  
WO/2017/151910A2
Disclosed are methods of selective cysteine and seienocysteine modification on peptide/protein molecules under physiologically relevant conditions. The methods feature several advantages over existing methods of peptide modification, suc...  
WO/2017/140183A1
Provided are substituted steroids and a use thereof. In particular, the substituted steroids of the present invention are steroids as shown by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer,...  
WO/2017/133360A1
Provided in the present invention are a steroidal compound, a composition containing the same and a use thereof. Specifically, disclosed in the present invention are a steroidal compound as shown in formula (I) and a drug composition con...  
WO/2017/134087A1
Steroidic calixarene compounds according to formula (I): (I) wherein: ∙ R represents -(CH2)x-L-(CH2)y-Ster, wherein : ○ x and y are integers comprised between 0 and 2; ○ n is an integer comprised between 1 and 5; ○ L represents a...  
WO/2017/129125A1
The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.  
WO/2017/120218A1
A combination therapy for the treatment of cancers refractory to anti-androgen therapy; particularly prostate cancer. The combination therapy includes a pharmaceutically effective amount of enzalutamide, bicalutamide, and/or abiraterone ...  
WO/2017/112904A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/106957A1
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/112909A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/112902A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/106957A8
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/101789A1
The present invention provides a compound having the structure (I), and pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, or prodrug thereof, and a method for preparing said compound; also provided is an application of ...  
WO/2017/062763A1
The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, as described herein. The present invention relates generally to FXR modulators and to methods of m...  
WO/2017/029664A1
A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromol...  
WO/2016/205475A3
The application relates to compounds of formula (A): or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, includin...  
WO/2016/205475A2
The application relates to compounds of formula (A): or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, includin...  
WO/2016/173397A1
The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative with the structure of formula (I), a stereoisomer, or...  
WO/2016/173524A1
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...  
WO/2016/173493A1
This disclosure is related to a sulfonylaminocarbonyl derivative of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the sulfonylaminocarbonyl derivatives of formula (I) and/or a phar...  
WO/2016/172517A1
Described herein are technologies and methods of use related to galeterone therapy regimens.  
WO/2016/164413A1
The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or inc...  
WO/2016/134301A2
Described herein are neuroactive steroids of the Formula (I): (I) or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behav...  
WO/2016/127876A1
The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2θ va...  
WO/2016/119742A1
The present invention relates to crystalline forms of (3β)-17-(1H-benzimidazole-1-yl)androstane-5, and 16-diene-3-ol phosphate, tartrate, and citrate and preparation methods therefor. Crystalline forms of phosphate, tartrate, and citrat...  
WO/2016/111216A1
In this organic electroluminescent device, which has a luminescent layer containing π-conjugated molecules, when the application of a current is stopped after the current is applied, light is emitted while the current is being applied a...  
WO/2016/102775A1
The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or ...  
WO/2016/102776A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prev...  
WO/2016/090139A1
Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined applicati...  
WO/2016/082789A1
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...  
WO/2016/086115A1
The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.  
WO/2016/082792A1
The present invention relates to a compound represented by general formula (I) and a stereoisomer or a pharmaceutically acceptable salt, and applications in the preparation of drugs used to prevent and treat cancers. The structure of the...  
WO/2016/057931A1
The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: (I), wherein A is an aryl or heteroaryl, each with or without subsutitution; and R1 is -H, -(alk...  
WO/2016/054472A1
Described herein are methods and compositions for the treatment of pancreatic cancer in a subject in need thereof. The pancreatic cancer may be resistant to other therapeutic regimens. The methods may comprise administering ARDA compound...  

Matches 1 - 50 out of 1,326